摘要
目的 探讨Notch信号通路在肝癌(HCC)细胞侵袭迁移中的作用机制.方法 分别用反转录-聚合酶链反应(RT-PCR)和Western blot检测肝癌细胞株HepG2和非肿瘤肝细胞株HL-7702中Snail和E-钙黏蛋白(E-cadherin)的mRNA和蛋白表达;Westem blot检测NICD蛋白的表达;200 pmol小干扰RNA(siRNA)-Snail和5μmol/L DAPT分别处理HepG2后,RT-PCR和Westem blot 检测Snail和E-cadherin的mRNA和蛋白表达;Transwell小室检测各处理组细胞的侵袭、迁移能力.结果 HepG2中Snail mRNA和蛋白的表达均高于非肿瘤肝细胞株HL-7702(0.11±0.06比0.08±0.02、0.46±0.06比0.21±0.04),差异有统计学意义(P =0.021、0.032),E-cadherin mRNA和蛋白的表达低于HL-7702(0.47±0.11比0.83±0.05、0.17 ±0.03比0.25±0.06),差异有统计学意义(P =0.012、0.004).与siRNA阴性对照组比较,siRNA-Snail组Snail mRNA(0.76±0.13比0.25±0.06,P=0.031)和蛋白(0.81±0.24比0.27 ±0.08,P=0.024)表达显著降低,E-cadherin mRNA(0.33±0.06比0.85±0.18,P=0.015)和蛋白(0.14 ±0.02比0.52 ±0.07,P=0.031)的表达显著上调,细胞侵袭(93.42±12.33比39.66±8.33,P=0.011)、迁移(375.66±65.21比98.52±12.76,P=0.008)能力均明显下降.HepG2中NICD蛋白的表达明显高于HL-7702(0.26±0.04比0.11±0.02),差异有统计学意义(P=0.004).与NT组比较,Notch信号通路特异性γ-分泌酶抑制剂(GSI)抑制剂DAPT能够降低NICD蛋白的表达(0.22±0.05,0.12 ±0.02,P=0.020),说明DAPT能够有效抑制Notch信号通路的活化.DAPT能有效抑制Snail mRNA(0.56±0.08比0.23±0.05,P=0.004)和蛋白(0.72 ±0.06比0.27±0.04,P=0.030)的表达,上调E-cadherin mRNA(0.21±0.03比0.54±0.06,P=0.011)和蛋白(0.32±0.07比0.77 ±0.08,P =0.021)的表达,同时能够抑制肝癌细胞的侵袭(87.33±9.33比32.21 ±6.63,P=0.008)、迁移(384.23±43.33比78.31±9.33,P=0.012).结论 Notch信号通路在肝癌侵袭迁移过程中起重要作用,其作用机制是通过调控Snail/E-cadherin来实现的.
Objective To investigate the mechanism of Notch signaling pathway in invasion and migration of hepatocellular carcinoma (HCC) cells.Methods The mRNA and protein expression levels of Snail and E-cadherin in hepatoma cells (HepG2) and non-tumor liver cell line (HL-7702) were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting respectively.Western blotting was used to detect the expression of NICD protein.The expression of Snail and E-cadherin mRNA and protein was detected by RT-PCR and Western blotting respectively after HepG2 cells were treated with 200 pmol small interfering RNA (siRNA)-Snail siRNA-Snail and 5 μmol/L DAPT.The invasive ability of HepG2 cells was examined by Transwell chamber.Results The expression levels of Snail mRNA and protein in HepG2 cells were significantly higher than those in HL-7702 cells (0.11 ±0.06 vs.0.08±0.02,P=0.021;0.46±0.06 vs.0.21 ±0.04,P=0.032).The expression levels of E-cadherin mRNA and protein in HepG2 cells were significantly lower than those in HL-7702 cells (0.47±0.11 vs.0.83±0.05,P=0.012;0.17±0.03 vs.0.25 ±0.06,P=0.004).As compared with the negative control group,the expression levels of Snail mRNA (0.76 ± 0.13 vs.0.25 ± 0.06,P =0.031) and protein (0.81 ± 0.24 vs.0.27 ± 0.08,P =0.024) in siRNA-Snail-treated group (Ss) decreased significantly,and the expression levels of E-cadherin mRNA (0.33 ± 0.06 vs.0.85 ± 0.18,P =0.015) and protein (0.14 ± 0.02 vs.0.52 ± 0.07,P =0.031) increased significantly,and the invasive ability (93.42 ± 12.33 vs.39.66 ± 8.33,P =0.011) and migration (375.66 ± 65.21 vs.98.52 ± 12.76,P =0.008) decreased significantly.The expression levels of NICD protein in HepG2 cells were significantly higher than those in HL-7702 cells (0.26 ± 0.04 vs.0.11 ± 0.02,P =0.004).As compared with NT group,the expression of NICD protein was significantly inhibited by Notch pathway selective inhibitor DAPT (0.22 ±0.05 vs.0.12 ±0.02,P =0.020),indicating that DAPT can effectively inhibit the activation of notch signaling pathway.The expression levels of Snail mRNA (0.56 ± 0.08 vs.0.23 ± 0.05,P =0.004) and protein (0.72 ± 0.06 vs.0.27 ± 0.04,P =0.030) could be down-regulated,and the expression levels of E-cadherin mRNA (0.21 ± 0.03 vs.0.54 ± 0.06,P =0.011) and protein (0.32 ±0.07 vs.0.77 ±0.08,P =0.021) could be upregulated by DAPT.Furthermore,DAPT could inhibit cell invasion (87.33 ±9.33 vs.32.21 ±6.63,P =0.008) and migration (384.23 ±43.33 vs.78.31 ± 9.33,P =0.012) in HepG2 cells.Conclusion Notch signaling pathway plays an important role in invasion and migration of HCC cells probably through the regulation of Snail/E-cadherin.
作者
李庆军
周进学
杨楠木
展翔宇
王征征
陈勋
朱瑞利
韩风
黄涛
Li Qingjun;Zhou Jinxue;Yang Nanmu;Zhan Xiangyu;Wang Zhengzheng;Chen Xun;Zhu Ruili;Han Feng;Huang Tao(Department of Hepatobiliary and Pancreatic Surgery, the Affiliated Tumor Hospital, Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Chin)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2018年第5期838-841,共4页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金(U1304818)